My Profile

Search abstracts

Lewis Sheiner


2020
Ljubljana, Slovenia



2019
Stockholm, Sweden
   Program
   Organisers
   Abstracts
   Participants

2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland


2019
   Stockholm, Sweden


IV-01 Christiane Dings
Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study
Thursday 15:25-16:50
IV-02 Anne-Gaelle Dosne
Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma
Thursday 15:25-16:50
IV-03 Erwin Dreesen
A population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy
Thursday 15:25-16:50
IV-04 Ronan Duchesne
Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis
Thursday 15:25-16:50
IV-05 Vincent Duval
A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab.
Thursday 15:25-16:50
IV-06 Dimitra Eleftheriadou
Aluminium biokinetics: Elucidating the speciation kinetics of the aluminium-citrate system in vitro.
Thursday 15:25-16:50
IV-07 Douglas J. Eleveld
Aging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions
Thursday 15:25-16:50
IV-08 Esther Encinas
Use of modeling and simulation methods to support the generic application of a vaginal delivery system
Thursday 15:25-16:50
IV-09 Aline Engbers
Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus
Thursday 15:25-16:50
IV-10 Muhammad Faisal
Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets.
Thursday 15:25-16:50
IV-11 Undine Falkenhagen
Structural model selection: Is the chi-square distribution appropriate for likelihood ratio tests?
Thursday 15:25-16:50
IV-12 Alan Faraj
Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients
Thursday 15:25-16:50
IV-13 Anam Fayyaz
Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes
Thursday 15:25-16:50
IV-14 Anam Fayyaz
Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes
Thursday 15:25-16:50
IV-15 Rebekka Fendt
Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations
Thursday 15:25-16:50
IV-16 Valentina Fermanelli
Correlation structure of Apolipoprotein A4, C3, E kinetics parameters
Thursday 15:25-16:50
IV-17 Chiara Fornari
Importance of stability analysis when using non-linear semi-mechanistic models to describe drug-induced haematotoxicity
Thursday 15:25-16:50
IV-18 Jose Francis
A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure
Thursday 15:25-16:50
IV-19 Yu Fu
Hemodynamic systems model to characterize cardiovascular drug effects
Thursday 15:25-16:50
IV-20 Aline Fuchs
Assessment of translation of PKPD relationship from animal to human for malaria compounds
Thursday 15:25-16:50
IV-21 Laura Fuhr
Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab
Thursday 15:25-16:50
IV-22 Masato Fukae
Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker
Thursday 15:25-16:50
IV-23 Fanny Gallais
Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies
Thursday 15:25-16:50
IV-24 Fiona G. Gao
Prediction of human pharmacokinetics of subcutaneously administered insulin formulations
Thursday 15:25-16:50
IV-25 Kamunkhwala Gausi
Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings
Thursday 15:25-16:50
IV-26 Sergey Gavrilov
Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer
Thursday 15:25-16:50
IV-27 Peter Gennemark
Determination of antisense oligonucleotide tissue half-life
Thursday 15:25-16:50
IV-28 Eva Germovsek
A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations
Thursday 15:25-16:50
IV-29 Bill Gillespie
Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation.
Thursday 15:25-16:50
IV-30 Anais Glatard
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling
Thursday 15:25-16:50
IV-31 Ferran Gonzalez
Pharmacokinetic model development for total and free vancomycin in critically ill children
Thursday 15:25-16:50
IV-32 Ignacio González
Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836)
Thursday 15:25-16:50
IV-33 Mario Gonzalez Sales
Assembling pharmacometric datasets in R: the puzzle package
Thursday 15:25-16:50
IV-34 Katharina Martha Götz
Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation
Thursday 15:25-16:50
IV-35 Iztok Grabnar
Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy
Thursday 15:25-16:50
IV-36 Silvia Grandoni
Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats
Thursday 15:25-16:50
IV-37 Ana-Marija Grisic
Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study
Thursday 15:25-16:50
IV-38 Jinju Guk
Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers
Thursday 15:25-16:50
IV-39 Tingjie Guo
Exploring practical limitations of model-based Bayesian dose optimization in intensive care patients
Thursday 15:25-16:50
IV-40 Stefanie Hamacher
Population pharmacokinetics of cannabidiol in healthy subjects
Thursday 15:25-16:50
IV-41 Felix Hammann
Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital
Thursday 15:25-16:50
IV-42 Lutz Harnisch
Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease
Thursday 15:25-16:50
IV-43 Paul Healy
PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain.
Thursday 15:25-16:50
IV-44 Guenter Heimann
An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy.
Thursday 15:25-16:50
IV-45 Farina Hellmann
Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example
Thursday 15:25-16:50
IV-46 Emilie Hénin
Therapeutic drug monitoring strategies for Envarsus in de novo renal transplant patients using population modelling and simulations
Thursday 15:25-16:50
IV-47 Charlotte Kloft
Review of NMLE articles published in clinical journals with a higher impact factor
Thursday 15:25-16:50
IV-48 Thomas Henthorn
A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data
Thursday 15:25-16:50
IV-49 Lukas Kovar
Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers
Thursday 15:25-16:50
IV-50 Anneke Himstedt
Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches.
Thursday 15:25-16:50
IV-51 Richard Höglund
Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach
Thursday 15:25-16:50
IV-52 Nick Holford
Rational dosing of caffeine using target concentration intervention to improve treatment of apnea of prematurity
Thursday 15:25-16:50
IV-53 Chih-hsuan Hsin
Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects
Thursday 15:25-16:50
IV-54 Ka Ho, Matthew Hui
Evaluation of Parameter Estimation when Fitting a Mixture Model with Covariate Effects using NONMEM
Thursday 15:25-16:50
IV-55 Ziad Hussein
Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia
Thursday 15:25-16:50
IV-56 Eman Ibrahim
Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort.
Thursday 15:25-16:50
IV-57 Hiroyuki Iida
Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice
Thursday 15:25-16:50
IV-58 Luis Ilia
Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid
Thursday 15:25-16:50
IV-59 Khalid Iqbal
Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin
Thursday 15:25-16:50
IV-60 Itziar Irurzun-Arana
ACESO (A Cancer Evolution Simulation Optimizer)
Thursday 15:25-16:50
IV-61 Kris Oliver Jalusic
Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients
Thursday 15:25-16:50
IV-62 Petra Jauslin
Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis
Thursday 15:25-16:50
IV-64 Jin Jin
Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling
Thursday 15:25-16:50
IV-65 Mats Jirstrand
A challenge model of TNFα turnover with LPS provocations and drug intervention
Thursday 15:25-16:50
IV-66 Curtis Johnston
M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM)
Thursday 15:25-16:50
IV-67 Daniel Jonker
The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin
Thursday 15:25-16:50
IV-68 Felix Jost
Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia
Thursday 15:25-16:50
IV-69 Fabian Jung
Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods
Thursday 15:25-16:50
IV-70 Wannee kantasiripitak
A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis
Thursday 15:25-16:50
IV-71 Evangelos Karakitsios
A methodology to estimate population pharmacokinetic parameters from aggregate concentration-time data and its application to gevokizumab.
Thursday 15:25-16:50
IV-72 Vangelis Karalis
An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies
Thursday 15:25-16:50
IV-73 Eleni Karatza
Investigation of the impact of population parameters describing gastric emptying on bioequivalence metrics
Thursday 15:25-16:50
IV-74 Tatiana Karelina
Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects
Thursday 15:25-16:50
IV-75 Adrien Tessier
Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I - simulation study evaluating type I error and power of proof-of-concept trials
Thursday 15:25-16:50
IV-76 Hidefumi Kasai
Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab
Thursday 15:25-16:50
IV-77 Takayuki Katsube
Evaluation of Variance-based Global Sensitivity Analysis for Covariate Effects
Thursday 15:25-16:50
IV-78 Aida Kawuma
Dolutegravir pharmacokinetics in co-administration with rifampicin.
Thursday 15:25-16:50
IV-79 Ron Keizer
Continuous learning in model-informed precision dosing: a case study
Thursday 15:25-16:50
IV-80 Zackary Kenz
Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model
Thursday 15:25-16:50
IV-81 Yun Kim
A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects
Thursday 15:25-16:50
IV-82 NaYoung Kim
Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy
Thursday 15:25-16:50
IV-83 Seoyoung Kim
Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale
Thursday 15:25-16:50
IV-84 Dohyun Kim
Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference
Thursday 15:25-16:50
IV-85 Lena Klopp-Schulze
Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development
Thursday 15:25-16:50
IV-86 Franziska Isabelle Kluwe
Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration
Thursday 15:25-16:50
IV-87 Lisa Alina Kneller
Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach
Thursday 15:25-16:50
IV-88 Stephan Koehne-Voss
A comparison of relative exposure estimates from single trough, multiple trough, and full population PK sampling designs
Thursday 15:25-16:50
IV-89 Galina Kolesova
Application of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies
Thursday 15:25-16:50